# US 2009/0264469 A1 · Novel dicarboxylic acid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0264469 A1
- Document ID: US20090264469A1
- Status: Published application
- Kind: A1
- Application number: 11/577,792
- Filed: 2005-10-18
- Published: 2009-10-22
- Earliest claimed: 2004-10-22
- Assignees: Bio-Projet; Sun Pharmaceutical Industries Limited
- Inventors: Marc Capet; Nicolas Levoin; Isabelle Berrebi-Bertrand; Olivia Poupardin; Philippe Robert; Jean-Charles Schwartz; Jeanne-Marie Lecomte; Thennati Rajamannar; Ranjan Kumar Pal; Biswajit Samanta; Jignesh K. Jivani; Bhavesh M. Panchal; Isha H. Bhatt; Jayraj D. Aradhye
- Web page: https://patentgrep.com/patent/US20090264469A1

## CPC

- C07C 237/24: having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 229/30: the carbon skeleton being acyclic and unsaturated
- C07C 229/48: with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
- C07C 323/12: the carbon skeleton being acyclic and saturated
- C07C 2601/08: the ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present patent application concerns new compounds of formula (I): displaying agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents.

## Claims

### Claim 1

A compound of formula (I):
wherein
Ar1 represents an Aryl or Heteroaryl group optionally substituted by 1 up to 5 R group(s),
wherein, each R, identical or different, is selected from the group consisting in Halogen atom, perhalogenoalkyl, -Alkyl, —OAlkyl, —OH, —COOR7, —CONR7R8, -Alkyl-Hal, —OAlkyl-Hal, NO2, —CN, —NR7R8, -AlkylAryl, -Aryl, —S(O)lR7, -Alkenyl, —Si(Alkyl)3;
wherein R7 and R8, identical or different, are chosen from the group consisting in H Alkyl; Cycloalkyl; Aryl; -AlkylAryl; Heteroaryl; wherein Alkyl, Cycloalkyl, and/or Aryl is(are) optionally substituted by one or more identical or different Halogen atom, polyfluoroalkyl, Aryl, —COOR7
or R7 and R8 form together with the N atom to which they are attached a Heterocycle;
l is 0, 1 or 2;
Y1 represents an -Alkyl-chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) and/or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)—, —C(═O)(OR7)-, —C(═O)(NR7)-, —N═N—, —S(O)l-;
m is 0 or 1;
X represents a heteroatom;
n is 0 or 1;
—Ar2- represents an -Aryl-group optionally substituted by one or more R group as defined above or wherein 2 R may form together with the atoms to which they are attached a fused cyclic, aryl or heteroaryl ring;
p is 0 or 1;
—Y2- represents an -Alkyl-chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)—, —C(═O)O—, —C(═O)(NR7), —N═N—, —S(O)l-;
R′represents a hydrogen atom, or a -Cycloalkyl or an -Alkyl chain, the cycloalkyl or alkyl being optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)O—, —C(═O)(NR7)-, —N═N—, —S(O)l-, such as -Alkenyl-Alkyl, -Alkynyl-Alkyl, —CH═N-Alkyl, —N═CH-Alkyl, —CH═N—O-Alkyl, —O—N═CH-Alkyl, —C(═O)-Alkyl, —C(═O)O-Alkyl, —C(═O)(NR7)-Alkyl, —N═N-Alkyl, —S(O)l-Alkyl;
—Y3- represents an -Alkyl-chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)—, —C(═O)O—, —C(═O)(NR7)-, —N═N—, —S(O)l-;
q is 0 or 1;
Z represents a -Cycloalkyl< group or an -Aryl<, -Heteroaryl< group or a —C(alkyl)< group, or R′ and Z form together with the N atom to which they are attached a Heterocyclic or Heteroaryl group;
wherein (CO2R″) and (COR′″) can be attached to the same atom or two adjacent atoms;
—R″ represents a hydrogen atom or an Alkyl chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s);
—R′″ represents —OH, —OAlkyl, H, —NR7OR8, —NR7R8, natural or synthetic amino acids, wherein R7 and R8 are defined as above;
or R″ and R′″ form together a ring with the atom(s) to which they are attached to form a cyclic intramolecular bis carbonyl group, including Meldrum acid derivatives;
as well as their enantiomers, diatereoisomers, geometrical isomers, mixtures thereof, free forms and pharmaceutically acceptable salts, hydrates, solvates and esters
with the exception of compounds where:
m=n=p=0, q=0 or 1, R′═H or Alkyl, Y2=-Alkyl-, Y3=-Alkyl-, Z=−C(Alkyl)< and Ar1=unsubstituted phenyl or phenyl substituted with one or more identical R where R is Halogen; and
m=n=p=0, q=1, R′═H, Y2=—CH2—, Y3=—CH2—, Z=-cyclobutyl< and Ar1=unsubstituted phenyl.

### Claim 2 (depends on 1)

Compound according to claim 1 represented by the following general formula (II):
in which Ar1, Y1, X, Ar2, Y2, R, R′, Y3, R″, R′″, m, n, p, q are defined as in formula (I) and
represents a -Cycloalkyl< group or an -Aryl<, -Heteroaryl< group;
wherein (CO2R″) and (COR′″) can be attached to the same atom or two adjacent atoms of the Z ring;
as well as their enantiomers, diatereoisomers, geometrical isomers, mixtures thereof, free forms and pharmaceutically acceptable salts, hydrates, solvates and esters.

### Claim 3 (depends on 1)

Compound according to claim 1, wherein:
Ar1 represents an Aryl or Heteroaryl group optionally substituted by 1 up to 5 R group(s),
wherein each R, identical or different, is selected from the group consisting in Halogen atom, perhalogenoalkyl, -Alkyl, —OAlkyl;
Y1 represents an -Alkyl-chain or a —S-Alkyl-chain;
m is 0 or 1;
X represents a heteroatom;
n is 0 or 1;
—Ar2- represents an -Aryl-group;
p is 0 or 1;
—Y2- represents an -Alkyl-chain;
—R′ represents a hydrogen atom or a cycloalkyl or an alkyl chain;
q is 0 or 1;
Y3 represents an alkynyl chain;
Z represents a —C(alkyl)< group or
represents a -Cycloalkyl< group;
—R″ represents a hydrogen atom; —R′″ represents —OH, —OAlkyl, —NR7R8;
(CO2R″) and (COR′″) are attached to the same atom of the Z ring;
as well as their enantiomers, diatereoisomers, geometrical isomers, mixtures thereof, free forms and pharmaceutically acceptable salts, hydrates, solvates and esters.

### Claim 4 (depends on 1)

Compound according to claim 1, wherein Ar1 represents a Phenyl or Thienyl group optionally substituted by 1 up to 5 R group(s),
wherein each R, identical or different, is selected from the group consisting in Halogen atom, perhalogenoalkyl Alkyl, —OAlkyl.

### Claim 5 (depends on 1)

Compound according to claim 1, wherein Y1 represents an -Alkyl-chain or a —S-Alkyl-chain.

### Claim 6 (depends on 1)

Compound according to claim 1, wherein m is 0.

### Claim 7 (depends on 1)

Compound according to claim 1, wherein X represents an Oxygen atom.

### Claim 8 (depends on 1)

Compound according to claim 1, wherein n is 0.

### Claim 9 (depends on 1)

Compound according to claim 1, wherein —Ar2- represents an -Phenyl-group.

### Claim 10 (depends on 1)

Compound according to claim 1, wherein p is 0.

### Claim 11 (depends on 1)

Compound according to claim 1, wherein —Y2- represents an -Alkyl-chain.

### Claim 12 (depends on 1)

Compound according to claims claim 1, wherein —R′ represents a hydrogen atom or a cycloalkyl or an alkyl chain, or —COOAlkyl.

### Claim 13 (depends on 1)

Compound according to claim 1, wherein q is 0.

### Claim 14 (depends on 2)

Compound according to
claim 2, wherein represents a -Cycloalkyl< group wherein (CO2R″) and (COR′″) are attached to the same atom of the Z ring.

### Claim 15 (depends on 1)

Compound according to claim 1, wherein —R″ represents a hydrogen atom.

### Claim 16 (depends on 1)

Compound according to claim 1, wherein —R′″ represents —OH, —OAlkyl, —NR7R8.

### Claim 17 (depends on 1)

Compound according to claim 1, selected from the group consisting in:
3-(4-octylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(4-octylbenzylamino)cyclopentane-1,1-dicarboxylic acid ethyl ester
3-(4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(4-octyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-methoxy-4-octyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-methoxy-4-butyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-methoxy-4-hexylyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-bromo-4-octyloxy-5-methoxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-methoxy-4-octyloxy-5-methylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-chloro-4-octyloxy-5-methoxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(4-decylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-methoxy-4-nonyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-chloro-4-nonyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-[4-[4-(4-methoxyphenyl)butoxy]benzylamino]cyclopentane-1,1-dicarboxylic acid
3-[4-[4-(3-chloro-4-methoxyphenyl)butoxy]benzylamino]-cyclopentane-1,1-dicarboxylic acid
3-(4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid ethyl ester hydrochloride
3-{4-[3-fluoro-(4-hexylphenyl)benzyl]amino}cyclopentane-1,1-dicarboxylic acid hydrochloride
1-(2,2,2-trifluoroethylcarbamoyl)-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid hydrochloride (isomer A)
1-(2,2,2-trifluoroethylcarbamoyl)-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid hydrochloride (isomer B)
3-(4-decyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid hydrochloride
1-(methylcarbamoyl)-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid hydrochloride (isomer A)
1-(methylcarbamoyl)-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid hydrochloride (isomer B)
3-(methyl-4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid hydrochloride
3-[4-(4-phenylsulfanylbutoxy)benzylamino]cyclopentane-1,1-dicarboxylic acid hydrochloride
3-[4-[4-(4-ethoxy-3-chlorophenyl)butoxy]benzylamino]cyclopentane-1,1-dicarboxylic acid hydrochloride
2-methyl-2-[4-(4-nonylbenzylamino)but-2-ynyl]malonic acid hydrochloride
2-[4-(3-chloro-4-nonyloxybenzylamino)but-2-ynyl]-2-methylmalonic acid hydrochloride
2-methyl-2-[4-(4-octylbenzylamino)but-2-ynyl]malonic acid hydrochloride
2-[4-(4-decylbenzylamino)but-2-ynyl]-2-methylmalonic acid hydrochloride
2-[3-fluoro-4-(4-hexylphenyl)benzylamino]but-2-ynyl]-2-methylmalonic acid hydrochloride
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]cyclopentane-1,1-dicarboxylic acid
1-Carbamoyl-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid—Isomer B
3-(3-Chloro-4-decyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(3-Chloro-4-octyloxybenzylamino)cyclopentane-1,1-dicarboxylic acid
1-Carbamoyl-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid—Isomer A
3-[Cyclopropyl-(4-nonylbenzyl)amino]cyclopentane-1,1-dicarboxylic acid
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-(2,3-Difluoro-4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(2,3-Difluoro-4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid ethyl ester
3-(4-Nonyl-benzylamino)cyclopentane-1,1-dicarboxylic acid isobutyl ester
3-[Methyl-(4-nonylbenzyl)amino]cyclopentane-1,1-dicarboxylic acid ethyl ester
3-(4-Nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid methyl ester
3-(4-Nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid benzyl ester
3-[(2-Fluoro-4′-octylbiphenyl-4-ylmethyl)amino]cyclopentane-1,1-dicarboxylic acid ethyl ester
3-[(2-Fluoro-4′-octylbiphenyl-4-ylmethyl)amino]cyclopentane-1,1-dicarboxylic acid
3-[Cyclopropyl-(2-fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]cyclopentane-1,1-dicarboxylic acid
3-(4-Nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid isopropylester
3-(2,3-Difluoro-4-nonylbenzylamino)-1-methylcarbamoylcyclopentane carboxylic acid—Isomer A
3-(2,3-Difluoro-4-nonylbenzylamino)-1-methylcarbamoylcyclopentane carboxylic acid—Isomer B
3-(4-Nonylbenzylamino)-1-propylcarbamoylcyclopentanecarboxylic acid—Isomer A
3-(4-Nonylbenzylamino)-1-propylcarbamoylcyclopentanecarboxylic acid—Isomer B
3-(4-Decyl-2,3-difluorobenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(4-Decylbenzylamino)-1-methylcarbamoylcyclopentanecarboxylic acid—Isomer A
3-(4-Decylbenzylamino)-1-methylcarbamoylcyclopentanecarboxylic acid—Isomer B
1-Ethylcarbamoyl-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid—Isomer A
1-Ethylcarbamoyl-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid—Isomer B
1-Isopropylcarbamoyl-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid-Isomer A
1-Isopropylcarbamoyl-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid-Isomer B
3-(4-Decyl-2,3-difluorobenzylamino)-1-methylcarbamoylcyclopentanecarboxylic acid—Isomer A
3-[(2,3-Difluoro-4-nonylbenzyl)methylamino]-1-methylcarbamoylcyclopentanecarboxylic acid—Isomer A
3-[(2,3-Difluoro-4-nonylbenzyl)methylamino]-1-methylcarbamoylcyclopentanecarboxylic acid—Isomer B
3-[(4-Decylbenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-(4-Nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid butyl ester
3-(4-Nonylbenzylaminocyclopentane-1,1-dicarboxylic acid propyl ester
1-(3,4-Difluorophenyl carbamoyl)-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid
3-[(2,3-Difluoro-4-nonylbenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-(4-Decyl-2,3-difluorobenzylamino)cyclopentane-1,1-dicarboxylic acid isopropyl ester
3-(4-Decylbenzylamino)cyclopentane-1,1-dicarboxylic acid isopropyl ester
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]-1-methylcarbamoylcyclopentanecarboxylic acid—Isomer A
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]-1-methylcarbamoylcyclopentanecarboxylic acid—Isomer B
3-(4-Decylbenzylamino)cyclopentane-1,1-dicarboxylic acid enantiomer A
3-(4-Decylbenzylamino)cyclopentane-1,1-dicarboxylic acid enantiomer B
3-[(3-Chloro-4-decyloxybenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-[(3-Chloro-4-nonylloxybenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
1-Dimethylcarbamoyl-3-(4-nonylbenzylamino)cyclopentanecarboxylic acid
1-Ethylcarbamoyl-3-(4-octylbenzylamino)cyclopentanecarboxylic acid—Isomer A
1-Ethylcarbamoyl-3-(4-octylbenzylamino)cyclopentanecarboxylic acid—Isomer B
1-Methylcarbamoyl-3-(4-octylbenzylamino)cyclopentanecarboxylic acid—Isomer A
1-Methylcarbamoyl-3-(4-octylbenzylamino)cyclopentanecarboxylic acid—Isomer B
3-(4-octylbenzylamino)cyclopentane-1,1-dicarboxylic acid isopropyl ester
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-(4-Decyl-2,3-difluorobenzylamino)cyclopentane-1,1-dicarboxylic acid enantiomer B
3-(4-Decyl-2,3-difluorobenzylamino)cyclopentane-1,1-dicarboxylic acid enantiomer A
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]cyclopentane-1,1-dicarboxylic acid enantiomer B
3-(4-Decylbenzylamino)cyclopentane-1,1-dicarboxylic acid ethyl ester—Isomer A
3-(4-Decylbenzylamino)cyclopentane-1,1-dicarboxylic acid ethyl ester—Isomer B
3-[(4-Decylbenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid ethyl ester
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid enantiomer B
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid ethyl ester enantiomer B
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid enantiomer A
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid ethyl ester enantiomer A
3-(4-Decyl-2,6-difluorobenzylamino)cyclopentane-1,1-dicarboxylic acid
3-[(4-Decyl-2,6-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)ethoxycarbonylamino]cyclopentane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)ethoxycarbonylamino]cyclopentane-1,1-dicarboxylic acid ethyl ester—Isomer A
3-[(4-Decyl-2,3-difluorobenzyl)ethoxycarbonylamino]cyclopentane-1,1-dicarboxylic acid ethyl ester—Isomer B
3-[(4-Decyl-2,3-difluorobenzyl)methoxycarbonylamino]cyclopentane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)methoxycarbonylamino]cyclopentane-1,1-dicarboxylic acid ethyl ester
2-Methyl-2-[4-(4-nonylbenzylamino)but-2-enyl]malonic acid
3-[2-(4-Octylphenyl)ethylamino]cyclopentane-1,1-dicarboxylic acid
1-(1-Carboxy-2-phenylethylcarbamoyl)-3-(4-nonylbenzylamino)cyclopentane-carboxylic acid
3-{4-[5-(3-Chloro-4-ethoxyphenyl)pentyloxy]benzylamino}cyclopentane-1,1-dicarboxylic acid
3-[4-(4-Phenyl-5-trifluoromethylthiophen-2-ylmethoxy)benzylamino]cyclopentane-1,1-dicarboxylic acid enantiomer B
3-{Methyl-[4-(4-phenyl-5-trifluoromethylthiophen-2-ylmethoxy)benzyl]amino}cyclopentane-1,1-dicarboxylic acid
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]cyclobutane-1,1-dicarboxylic acid
3-(4-Nonylbenzylamino)cyclobutane-1,1-dicarboxylic acid
3-(4-Decylbenzylamino)cyclobutane-1,1-dicarboxylic acid
3-[(4-Decylbenzyl)methylamino]cyclobutane-1,1-dicarboxylic acid
3-(4-Decyl-2,3-difluorobenzylamino)cyclobutane-1,1-dicarboxylic acid
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]-1-methylcarbamoylcyclobutanecarboxylic acid—Isomer A
3-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]-1-methylcarbamoylcyclobutanecarboxylic acid—Isomer B
3-[(4-Decylbenzyl)methylamino]cyclobutane-1,1-dicarboxylic acid ethyl ester
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclobutane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclobutane-1,1-dicarboxylic acid ethyl ester
3-[4-(4-Phenyl-5-trifluoromethylthiophen-2-ylmethoxy)benzylamino]cyclobutane-1,1-dicarboxylic acid
1-(4-Decylbenzyl)piperidine-4,4-dicarboxylic acid
1-(4-Nonylbenzyl)piperidine-4,4-dicarboxylic acid
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid
1-(4-Octylbenzyl)piperidine-4,4-dicarboxylic acid
1-(3-Chloro-4-nonyloxybenzyl)piperidine-4,4-dicarboxylic acid
1-(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)piperidine-4,4-dicarboxylic acid
1-(4-Decylbenzyl)piperidine-4,4-dicarboxylic acid ethyl ester
1-(3-Chloro-4-decyloxybenzyl)piperidine-4,4-dicarboxylic acid ethyl ester
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid ethyl ester
1-(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)piperidine-4,4-dicarboxylic acid ethyl ester
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid methyl ester
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid isopropyl ester
1-(4-Decylbenzyl)-4-ethylcarbamoylpiperidine-4-carboxylic acid
1-(4-Decylbenzyl)-4-propylcarbamoylpiperidine-4-carboxylic acid
1-(2,3-difluoro-4-nonylbenzyl)-4-ethylcarbamoylpiperidine-4-carboxylic acid
4-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclohexane-1,1-dicarboxylic acid diethyl ester
4-[(2,3-Difluoro-4-nonylbenzyl)methylamino]cyclohexane-1,1-dicarboxylic acid diethyl ester
4-(2,3-Difluoro-4-nonylbenzylamino)cyclohexane-1,1-dicarboxylic acid
4-[(2,3-Difluoro-4-nonylbenzyl)methylamino]cyclohexane-1,1-dicarboxylic acid ethyl ester
4-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclohexane-1,1-dicarboxylic acid ethyl ester
4-(4-Decyl-2,3-difluorobenzylamino)cyclohexane-1,1-dicarboxylic acid
4-[(2,3-Difluoro-4-nonylbenzyl)methylamino]cyclohexane-1,1-dicarboxylic acid
4-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclohexane-1,1-dicarboxylic acid
1-[4-(4-Phenyl-5-trifluoromethylthiophen-2-ylmethoxy)benzyl]-piperidine-4,4-dicarboxylic acid
1-(4-Decylbenzyl)azetidine-3,3-dicarboxylic acid
2-[4-(3-Chloro-4-decyloxybenzylamino)but-2-ynyl]-2-methylmalonic acid
2-{4-[(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)amino]but-2-ynyl}-2-methylmalonic acid
2-{4-[Isopropyl(4-nonylbenzyl)amino]but-2-ynyl}-2-methylmalonic acid
2-{4-[Cyclopropyl(4-nonylbenzyl)amino]but-2-ynyl}-2-methylmalonic acid
2-{4-[(2-Fluoro-4′-hexylbiphenyl-4-ylmethyl)methylamino]but-2-ynyl}-2-methylmalonic acid
2-Methyl-2-{4-[methyl(4-nonylbenzyl)amino]but-2-ynyl}malonic acid
2-{4-[(2,3-Difluoro-4-nonylbenzyl)methylamino]but-2-ynyl}-2-methylmalonic acid.
2-{4-[Ethyl-(4-nonylbenzyl)amino]but-2-ynyl}-2-methylmalonic acid
2-{4-[(2,3-Difluoro-4-nonylbenzyl)amino]but-2-ynyl}-2-methylmalonic acid
2-[4-(4-Decyl-2,3-difluorobenzylamino)but-2-ynyl]-2-methylmalonic acid
2-{4-[(4-Decylbenzyl)methylamino]but-2-ynyl}-2-methylmalonic acid
2-{4-[(3-Chloro-4-nonyloxybenzyl)methylamino]but-2-ynyl}-2-methylmalonic acid.
2-Ethyl-2-{4-[(2-fluoro-4′-hexylbiphenyl-4-ylmethyl)amino]but-2-ynyl}malonic acid
2-Methyl-2-{4-[4-(4-phenyl-5-trifluoromethylthiophen-2-ylmethoxy)benzylamino]but-2-ynyl}malonic acid
as well as their enantiomers, diatereoisomers, geometrical isomers, mixtures thereof,
free forms and pharmaceutically acceptable salts, hydrates, solvates and esters.

### Claim 18 (depends on 1)

Compound according to claim 1, selected from the group consisting in:
3-(4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(4-decylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-(methyl-4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid hydrochloride
3-(2,3-Difluoro-4-nonylbenzylamino)cyclopentane-1,1-dicarboxylic acid
3-[Methyl-(4-nonylbenzyl)amino]cyclopentane-1,1-dicarboxylic acid ethyl ester
3-(4-Decyl-2,3-difluorobenzylamino)cyclopentane-1,1-dicarboxylic acid
3-[(2,3-Difluoro-4-nonylbenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid enantiomer B
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid enantiomer B
3-[(4-Decyl-2,3-difluoro-benzyl)methylamino]-cyclopentane-1,1-dicarboxylic acid ethyl ester enantiomer B
3-[(4-Decyl-2,3-difluoro-benzyl)methylamino]-cyclopentane-1,1-dicarboxylic acid ethyl ester enantiomer A
3-[(4-Decyl-2,6-difluorobenzyl)methylamino]cyclopentane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclobutane-1,1-dicarboxylic acid
3-[(4-Decyl-2,3-difluorobenzyl)methylamino]cyclobutane-1,1-dicarboxylic acid ethyl ester
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid
1-(2-Fluoro-4′-heptylbiphenyl-4-ylmethyl)piperidine-4,4-dicarboxylic acid
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid ethyl ester
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid methyl ester
1-(4-Decyl-2,3-difluorobenzyl)piperidine-4,4-dicarboxylic acid isopropyl ester
1-(2,3-difluoro-4-nonylbenzyl)-4-ethylcarbamoyl piperidine-4-carboxylic acid
as well as their enantiomers, diastereoisomers, geometrical isomers, mixtures thereof, free forms and pharmaceutically acceptable salts, hydrates, solvates and esters.

### Claim 19 (depends on 1)

Process of preparation of a compound according to claim 1, further comprising the step of reacting a compound of formula (III):
with a compound of formula (IV):
O═(Y3′)q-Z(CO2R″)(COR′″) (IV)
wherein Ar1, Y1, X, Ar2, Y2, R′, Z, R″, R′″, m, n, p, q are defined as in formula (I), provided that when q=0, the keto function is attached to a carbon atom of Z, and when q=1, Y3′ is such that —CH2-Y3′- corresponds to Y3 as defined in formula (I).

### Claim 20 (depends on 19)

Process according to claim 19, wherein said reaction is carried out under reductive amination conditions.

### Claim 21 (depends on 1)

Process of preparation of a compound according to claim 1, comprising the step of reacting a compound of formula (V):
Ar1(Y1)m-(X)n-(Ar2)p-Y2-SO2Alkyl (V)
with a compound of formula (IX):
wherein Ar1, Y1, X, Ar2, Y2, R′, Y3, Z, R″, R′″, m, n, p, q are defined as in formula (I).

### Claim 22 (depends on 21)

Process according to claim 21, wherein said reaction is carried out under nucleophilic displacement conditions.

### Claim 23 (depends on 1)

Process of preparation of a compound according to claim 1, comprising the step of reacting a compound of formula (VII):
Ar1-(Y1)m-(X)n-(Ar2)p—Y2=O (VII)
with a compound of formula (X):
H2N(Y3′)q-Z-(CO2R″)(COR′″) (X)
wherein Ar1, Y1, X, Ar2, Y2, Z, R″, R′″, m, n, p, q are defined as in formula (I), Y3′ is such that —CH2-Y3′- corresponds to Y3 as defined in formula (I).

### Claim 24 (depends on 23)

Process according to claim 23, wherein said reaction is carried out under reductive conditions.

### Claim 25 (depends on 19, 20, 21, 22)

Process according to claim 19 to 22 claim 19, wherein said coupling reaction is followed by further modifying Ar1, Y1, X, Ar2, Y2, R′, Z, R″, R′″ of the compound of formula (I) obtained so as to obtain the desired compound of formula (I).

### Claim 26 (depends on 19)

Process according to claim 19, which further comprises the additional step of isolating the compound of formula (I).

### Claim 27 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) according to claim 1 with a pharmaceutically acceptable excipient or carrier.

### Claim 28

Use of a compound of formula (I)
wherein
Ar1 represents an Aryl or Heteroaryl group optionally substituted by 1 up to 5 R group(s),
wherein, each R, identical or different, is selected from the group consisting in Halogen atom, perhalogenoalkyl, -Alkyl, —OAlkyl, —OH, —COOR7, —CONR7R8, -Alkyl-Hal, —OAlkyl-Hal, NO2, —CN, —NR7R8, -AlkylAryl, -Aryl, —S(O)lR7, -Alkenyl, —Si(Alkyl);
wherein R7 and R8, identical or different, are chosen from the group consisting in H Alkyl; Cycloalkyl; Aryl; -AlkylAryl; Heteroaryl; wherein Alkyl, Cycloalkyl, and/or Aryl is(are) optionally substituted by one or more identical or different Halogen atom, polyfluoroalkyl, Aryl, —COOR7
or R7 and R8 form together with the N atom to which they are attached a Heterocycle;
l is 0, 1 or 2;
Y1 represents an -Alkyl-chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) and/or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)—, —C(═O)(OR7)-, —C(═O)(NR7)-, —N═N—, —S(O)l-;
m is 0 or 1;
X represents a heteroatom;
n is 0 or 1;
—Ar2- represents an -Aryl-group optionally substituted by one or more R group as defined above or wherein 2 R may form together with the atoms to which they are attached a fused cyclic, aryl or heteroaryl ring;
p is 0 or 1;
—Y2- represents an -Alkyl-chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)—, —C(═O)O—, —C(═O)(NR7), —N═N—, —S(O)l-;
—R′ represents a hydrogen atom, or a -Cycloalkyl or an -Alkyl chain, the cycloalkyl or alkyl being optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)—, —C(═O)O—, —C(═O)(NR7)-, —N═N—, —S(O)l-, such as -Alkenyl-Alkyl, -Alkynyl-Alkyl, —CH═N-Alkyl, —N═CH-Alkyl, —CH═N—O-Alkyl, —O—N═CH-Alkyl, —C(═O)-Alkyl, —C(═O)O-Alkyl, —C(═O)(NR7)-Alkyl, —N═N-Alkyl, —S(O)l-Alkyl;
—Y3- represents an -Alkyl-chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s) or heteroatom(s) and/or a residue chosen from the group consisting in -Alkenyl-, -Alkynyl-, —CH═N—, —N═CH—, —CH═N—O—, —O—N═CH—, —C(═O)—, —C(═O)O—, —C(═O)(NR7)-, —N═N—, —S(O)l-;
q is 0 or 1;
Z represents a -Cycloalkyl< group or an -Heterocyclic<, -Aryl<, -Heteroaryl< group or a —CH<, —C(alkyl)< group, or R′ and Z form together with the N atom to which they are attached a Heterocyclic or Heteroaryl group;
wherein (CO2R″) and (COR′″) can be attached to the same atom or two adjacent atoms;
—R″ represents a hydrogen atom or an Alkyl chain, optionally substituted by one or more R as defined above, and optionally comprising one or more unsaturation(s);
—R′″ represents —OH, —OAlkyl, H, —NR7OR8, —NR7R8, natural or synthetic amino acids, wherein R7 and R8 are defined as above;
or R″ and R′″ form together a ring with the atom(s) to which they are attached to form a cyclic intramolecular bis carbonyl group, including Meldrum acid derivatives;
as well as their enantiomers, diatereoisomers, geometrical isomers, mixtures thereof, free forms and pharmaceutically acceptable salts, hydrates, solvates and esters for the preparation of a medicament acting as an agonist at human S1P1 receptors selectively, for administration to a patient in the need thereof.

### Claim 29 (depends on 1, 28)

Use according to claim 28, wherein said compound is defined as in claim 1.

### Claim 30 (depends on 28)

Use according to claim 28, wherein said compound interacts with sphingosine phosphate receptor.

### Claim 31 (depends on 28)

Use according to claim 28, wherein said compound acts as an agonist at sphingosine phosphate receptor.

### Claim 32 (depends on 28)

Use according to claim 28, wherein said compound is suitable for decreasing circulating lymphocytes in blood in a patient in the need thereof.

### Claim 33 (depends on 28)

Use according to claim 28, wherein said compound is for treating and/or preventing transplant rejection, immune disorders, autoimmune disorders, inflammatory and chronic inflammatory conditions that include rheumatoid arthritis, asthma, pollinosis, psoriasis, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulo-nephritis, atherosclerosis, multiorgan failure, sepsis, pneumonia as well as disorders related to impaired vascular integrity, deregulated angiogenesis.

### Claim 34 (depends on 28)

Use according to claim 28, wherein said medicament is for treating and/or preventing tissue graft rejection.
